RBR 52(6) - Book.indb - Sociedade Brasileira de Reumatologia
RBR 52(6) - Book.indb - Sociedade Brasileira de Reumatologia RBR 52(6) - Book.indb - Sociedade Brasileira de Reumatologia
Londono et al. AGRADECIMENTOS Ao Dr. Carlos Bustamante e ao Dr. Carlos Granados, pelas recomendações técnicas e metodológicas que nos permitiram desenvolver adequadamente este projeto. A Renato Guzmán, León Felipe Jaramillo, Fernando Medina, José Fernando Molina, Juan José Jaller, Elias Forero, Javier Ramírez, Mauricio Abello, William Otero, Mario Díaz, Edgardo Tobías, Patricia Vélez e María Jose Janaut, que participaram como investigadores principais em cada um dos centros realizadores da investigação. REFERENCES REFERÊNCIAS 1. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93(4):551–6. 2. Lawrence R, Helmick C, Arnett F, Deyo R, Felson D, Giannini E et al. Estimates of the prevalence of arthritis and selected musculoskeletal. Arthritis Rheum 1998; 41(5):778–99. 3. Anaya JM, Correa PA, Mantilla RD, Jimenez F, Kuffner T, McNicholl JM. Rheumatoid arthritis in African Colombians from Quibdo. Semin Arthritis Rheum 2001; 31(3):191–8. 4. Spindler A, Bellomio V, Berman A, Lucero E, Baigorria M, Paz S et al. Prevalence of rheumatoid arthritis in Tucuman, Argentina. J Rheumatol 2002; 29(6):1166–70. 5. Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 2004; 31(3):594–7. 6. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002; 20(5):617–24. 7. Cardiel MH. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(Suppl 2):ii7–ii22. 8. O’Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334(20):1287–91. 9. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V et al. Mechanism of action for lefl unomide in rheumatoid arthritis. Clin Immunol 1999; 93(3):198–208. 10. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al. Treatment of active rheumatoid arthritis with lefl unomide compared with placebo and methotrexate. Lefl unomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159(21):2542–50. 11. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al. Effi cacy and safety of lefl unomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Lefl unomide Study Group. Lancet 1999; 353(9149):259–66. 12. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42(7):1322–8. 13. Alves JA, Fialho SC, Morato EF, Castro GR, Zimmermann AF, Ribeiro GG et al. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with lefl unomide and methotrexate. Rev Bras Reumatol 2011; 51(2):141–4. 14. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al. Concomitant lefl unomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137(9):726–33. 15. Furst D, Luggen M, Thompson A, Colleman J. Adding lefl unomide to patients with active rheumatoid arthritis while receiving methotrexate improves physical function and health-related quality of life Arthritis Rheum. [Abstract]. 2000; 43:S344. 16. Bertolo MB, Brenol CV, Schainberg CG, Neubarth F, Lima FACd, Laurindo IM et al. Update on the Brazilian Consensus for the Diagnosis and Treatment of Rheumatoid Arthritis. Ver Bras Reumatol 2007; 47:151–9. 17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum 1988; 31(3):315–24. 18. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American College of Rheumatology. Preliminary defi nition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6):727–35. 19. Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI et al. Combination treatment with lefl unomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol 2009; 38(1):11–4. 20. Antony T, Jose VM, Paul BJ, Thomas T. Effi cacy and safety of lefl unomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian J Med Sc 2006; 60(8):318–26. 21. Uribe-Caballero CV, Chalem P, Londoño J. Tratamiento de la Artritis Reumatoide en Colombia. Aplicación práctica de los conceptos teóricos por parte de los reumatólogos colombianos. Rev Colomb Reumatol 2002; 9(4):242–50. 22. Mottonen TT, Hannonen PJ, Boers M. Combination DMARD therapy including corticosteroids in early rheumatoid arthritis. Clin Exp Rheumatol 1999; 17(6 Suppl 18):S59–65. 23. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333(3):137–41. 24. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfi eld JP et al. The immunosuppressant lefl unomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275(2):1043–9. 25. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39(12):1951–60. 26. Van Riel P. Lefl unomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate. Clin Exp Rheumatol 2003; 21(6):695–6. 844 Rev Bras Reumatol 2012;52(6):830-845
27. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C et al. Function and health-related quality of life: results from a randomized controlled trial of lefl unomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Lefl unomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999; 42(9):1870–8. 28. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of lefl unomide: an appraisal of lefl unomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32(12):1123–34. 29. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54(2):628–34. 30. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105(11):2396–404. 31. Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a patient receiving methotrexate and lefl unomide. Arthritis Rheum 2000; 43(11):2609–11. Metotrexato + lefl unomida para tratamento da artrite reumatoide 32. Dougados M, Emery P, Lemmel EM, de la Serna R, Zerbini CA, Brin S et al. Effi cacy and safety of lefl unomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003; 30(12):2572–9. 33. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P et al. Lefl unomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30(6):1182–90. 34. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68(7):1100–4. 35. Maddison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D et al. Lefl unomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 2005; 44(3):280–6. 36. Pineda-Tamayo R, Arcila G, Restrepo P, Tobón GJ, Camargo J, Anaya JM. Costos médicos directos dela artritis reumatoide temprana. Rev Colomb Reumatol 2005; 11(2):89–96. 37. Mora C, Gonzalez A, Diaz J, Quintana G. Financial cost of early rheumatoid arthritis in the fi rst year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia. Biomedica 2009; 29(1):43–50. Rev Bras Reumatol 2012;52(6):830-845 845
- Page 1 and 2: BRAZILIAN JOURNAL OF RHEUMATOLOGY R
- Page 3 and 4: EDITORIAL Anticorpos antinucleossom
- Page 5 and 6: Incapacitação e qualidade de vida
- Page 7 and 8: Anti-CCP Incapacitação e qualidad
- Page 9 and 10: Incapacitação e qualidade de vida
- Page 11 and 12: ARTIGO ORIGINAL Efi cácia terapêu
- Page 13 and 14: - hemograma, velocidade de hemossed
- Page 15 and 16: Resposta ACR Depois da semana 6 com
- Page 17: espiratórios e sintomas relacionad
- Page 21 and 22: Silva et al. Contudo, considerando
- Page 23 and 24: Silva et al. Pittisburgh 60 40 20 0
- Page 25 and 26: Silva et al. CONCLUSÃO A hidrocine
- Page 27 and 28: ARTIGO ORIGINAL Níveis séricos de
- Page 29 and 30: Níveis séricos de vitamina B12 n
- Page 31 and 32: Níveis séricos de vitamina B12 n
- Page 33 and 34: Níveis séricos de vitamina B12 n
- Page 35 and 36: Impacto dos exercícios na capacida
- Page 37 and 38: Impacto dos exercícios na capacida
- Page 39 and 40: Impacto dos exercícios na capacida
- Page 41 and 42: ARTIGO ORIGINAL Atividade sexual na
- Page 43 and 44: Tabela 1 Dados demográfi cos - gru
- Page 45 and 46: 18. Daltroy LH, Larson MG, Roberts
- Page 47 and 48: Souza et al. O objetivo do presente
- Page 49 and 50: Souza et al. Tabela 5 Comorbidades
- Page 51 and 52: Souza et al. extramusculares; e ín
- Page 53 and 54: Carvalho et al. e indiferenciada. 4
- Page 55 and 56: Carvalho et al. osteoblastos. 11,13
- Page 57 and 58: ARTIGO DE REVISÃO Análise farmaco
- Page 59 and 60: Brandão et al. Análises econômic
- Page 61 and 62: Brandão et al. Tabela 1 Caracterí
- Page 63 and 64: Brandão et al. Tabela 2 Resultados
- Page 65 and 66: Brandão et al. Tabela 2 Resultados
- Page 67 and 68: Brandão et al. Dos estudos analisa
27. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B,<br />
Dorrier C et al. Function and health-related quality of life:<br />
results from a randomized controlled trial of lefl unomi<strong>de</strong> versus<br />
methotrexate or placebo in patients with active rheumatoid arthritis.<br />
Lefl unomi<strong>de</strong> Rheumatoid Arthritis Investigators Group. Arthritis<br />
Rheum 1999; 42(9):1870–8.<br />
28. Alcorn N, Saun<strong>de</strong>rs S, Madhok R. Benefit-risk assessment of<br />
lefl unomi<strong>de</strong>: an appraisal of lefl unomi<strong>de</strong> in rheumatoid arthritis 10<br />
years after licensing. Drug Saf 2009; 32(12):1123–34.<br />
29. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis<br />
and the risk of hospitalization for pneumonia: associations with<br />
prednisone, disease-modifying antirheumatic drugs, and anti-tumor<br />
necrosis factor therapy. Arthritis Rheum 2006; 54(2):628–34.<br />
30. Devarbhavi H, Dierkhising R, Kremers WK, San<strong>de</strong>ep MS,<br />
Karanth D, Adarsh CK. Single-center experience with drug-induced<br />
liver injury from India: causes, outcome, prognosis, and predictors<br />
of mortality. Am J Gastroenterol 2010; 105(11):2396–404.<br />
31. Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a<br />
patient receiving methotrexate and lefl unomi<strong>de</strong>. Arthritis Rheum<br />
2000; 43(11):2609–11.<br />
Metotrexato + lefl unomida para tratamento da artrite reumatoi<strong>de</strong><br />
32. Dougados M, Emery P, Lemmel EM, <strong>de</strong> la Serna R, Zerbini CA,<br />
Brin S et al. Effi cacy and safety of lefl unomi<strong>de</strong> and predisposing<br />
factors for treatment response in patients with active rheumatoid<br />
arthritis: RELIEF 6-month data. J Rheumatol 2003; 30(12):2572–9.<br />
33. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V,<br />
Tugwell P et al. Lefl unomi<strong>de</strong> for the treatment of rheumatoid<br />
arthritis: a systematic review and metaanalysis. J Rheumatol 2003;<br />
30(6):1182–90.<br />
34. Salliot C, van <strong>de</strong>r Heij<strong>de</strong> D. Long-term safety of methotrexate<br />
monotherapy in patients with rheumatoid arthritis: a systematic<br />
literature research. Ann Rheum Dis 2009; 68(7):1100–4.<br />
35. Maddison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D<br />
et al. Lefl unomi<strong>de</strong> in rheumatoid arthritis: recommendations through<br />
a process of consensus. Rheumatology (Oxford) 2005; 44(3):280–6.<br />
36. Pineda-Tamayo R, Arcila G, Restrepo P, Tobón GJ, Camargo J,<br />
Anaya JM. Costos médicos directos <strong>de</strong>la artritis reumatoi<strong>de</strong><br />
temprana. Rev Colomb Reumatol 2005; 11(2):89–96.<br />
37. Mora C, Gonzalez A, Diaz J, Quintana G. Financial cost of early<br />
rheumatoid arthritis in the fi rst year of medical attention: three<br />
clinical scenarios in a third-tier university hospital in Colombia.<br />
Biomedica 2009; 29(1):43–50.<br />
Rev Bras Reumatol 2012;<strong>52</strong>(6):830-845 845
Change language